Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024
Both ADC candidates are optimized for long-lasting, durable tumor engagement and minimal off-target toxicity.
- Both ADC candidates are optimized for long-lasting, durable tumor engagement and minimal off-target toxicity.
- The results we will present at the AACR Annual Meeting will highlight the preclinical differentiation of our two lead candidates, TUB-030 and TUB-040.
- The full abstracts will be published on March 22, 2024, in an online-only proceedings supplement to the AACR journal, Cancer Research.
- The company will issue a press release detailing the full preclinical data following the presentation at AACR.